Articles related to MYOCARDITIS
COVID-19 Vaccination–Associated Myocarditis in Adolescents
A new study published in Pediatrics concludes that there is a quick clinical recovery and excellent short-term outcomes for adolescents who develop COVID-19-related vaccination-associated myocarditis (C-VAM). The average age in the study was 15, and close follow-up and further studies are needed to understand the long-term implications and mechanism of these myocardial tissue changes.
Cardiology November 9th 2021
CDC Confirms 226 Cases of Myocarditis After COVID-19 Vaccination in People 30 and Under
The data was presented to the FDA, which reported 789 cases of myocarditis/pericarditis – predominantly in males – after receiving the Pfizer/BioNTech and Moderna vaccines, most commonly after the second dose. Symptoms included chest pain, elevated cardiac enzymes, ST or T wave changes, dyspnea, and abnormal echocardiography/imaging for those ages 30 years and younger.
Cardiology June 15th 2021
CDC Releases Guidance for Clinicians on Heart Inflammation After COVID-19 Vaccination
Since April 2021, there have been reports of myocarditis and/or pericarditis after receipt of an m-RNA COVID-19 vaccine, according to the Centers for Disease Control and Prevention (CDC) . Most cases have been among male adolescents and young adults ages 16 and older, typically occurring within several days after the second dose of m-RNA COVID-19 vaccine.
Cardiology June 2nd 2021